Inmune Bio Stock In The News

INMB Stock  USD 1.51  0.02  1.34%   
Our overall analysis of INmune Bio's news coverage and content from conventional and social sources shows investors' bearish mood towards INmune Bio. The specific impact of INmune Bio news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of INmune Bio's overall financial health and prospects. It also depends on the type and quality of a news publisher. Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using INmune Bio headlines in addition to utilizing other, more conventional financial analysis modules. Check out INmune Bio Backtesting and INmune Bio Hype Analysis.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

INmune Bio Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
https://www.globenewswire.com/news-release/2025/11/18/3189923/0/en/INmune-Bio-Announces-Two-Presentations-at-the-Upcoming-18th-Annual-CTAD-Conference.html
 Neutral
Yahoo News
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
https://finance.yahoo.com/news/inmune-bio-inmb-could-support-145502822.html
 Bullish
Macroaxis News: globenewswire.com
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
https://www.globenewswire.com/news-release/2025/10/30/3177900/0/en/INmune-Bio-Inc-Announces-Third-Quarter-2025-Results-and-Provides-Business-Update.html
 Neutral
seekingalpha News
INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift
https://seekingalpha.com/news/4482843-inmune-bio-outlines-cordstrom-bla-and-maa-filings-targeted-for-midminus-2026-as-ceo?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
 Bullish
Investing News at Macroaxis
INmune Bio August 2025 slides: three-platform strategy shows clinical progress
https://www.investing.com/news/company-news/inmune-bio-august-2025-slides-threeplatform-strategy-shows-clinical-progress-93CH-4179058
 Bullish
Macroaxis News: globenewswire.com
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes
https://www.globenewswire.com/news-release/2025/08/07/3129702/0/en/INmune-Bio-Inc-Announces-Second-Quarter-2025-Results-Provides-Business-Update-and-Announces-Management-Changes.html
 Neutral
news
What's going on in today's pre-market session
https://www.chartmill.com/news/PBM/Chartmill-32213-Whats-going-on-in-todays-pre-market-session
 Bullish
Macroaxis News: globenewswire.com
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
https://www.globenewswire.com/news-release/2025/07/31/3124830/0/en/INmune-Bio-Inc-to-Report-Second-Quarter-2025-Financial-Results-and-Provide-Corporate-Update-on-Thursday-August-7th.html
 Neutral
Macroaxis News: globenewswire.com
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
https://www.globenewswire.com/news-release/2025/07/29/3123091/0/en/INmune-Bio-to-Publish-Video-Detailing-MINDFuL-Trial-Findings-of-XPro-Presented-at-the-Alzheimer-s-Association-International-Conference.html
 Neutral
Investing News at Macroaxis
INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss
https://www.investing.com/news/stock-market-news/inmune-slides-again-as-scotiabank-rj-cut-ratings-after-alzheimers-drug-miss-4119860
 Neutral

INmune Bio Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide INmune and other traded companies coverage with news coverage. We help investors stay connected with INmune headlines for the 23rd of November to make an informed investment decision based on correlating the impacts of news items on INmune Stock performance. Please note that trading solely based on the INmune Bio hype is not for everyone as timely availability and quick action are needed to avoid losses.
INmune Bio's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help INmune Bio investors visualize upcoming and past events in order to time the market based on INmune Bio noise-free hype analysis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards INmune Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, INmune Bio's short interest history, or implied volatility extrapolated from INmune Bio options trading.
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
Check out INmune Bio Backtesting and INmune Bio Hype Analysis.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
0.002
Quarterly Revenue Growth
2.571
Return On Assets
(0.51)
Return On Equity
(1.56)
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.